Bagian Makalah:  

1. Increased body mass index is associated with improved overall survival in extranodal    natural killer/T-cell lymphoma, nasal type.       Oncotarget. 2017, Vol. 8, (No. 3), pp: 4245-4256. IF: 5.17  Ya-Jun Li1, Ping-Yong Yi (Corresponding author), Ji-Wei Li,

2. Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study. Chinese Journal of Cancer. (2017) 36:62. IF: 4.11        YaJun Li, PingYong Yi (Corresponding author), JiWei Li,

3. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.  Biochemical and Biophysical Research Communications. 2017 Jul 26. IF: 2.47 Jin Li, Changgeng Qian, Qianqian Zhou, Jiwei Li, Kunlun Li, Pingyong Yi (Corresponding author)  

4. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.  Journal of Hematology & Oncology. 2017 Mar 15;10(1):69. IF: 6.35   Yuankai Shi, Bo Jia, Wei Xu, Wenyu Li, Ting Liu, Peng Liu, Weili Zhao, Huilai Zhang, Xiuhua Sun, Haiyan Yang, Xi Zhang, Jie Jin, Zhengming Jin, Zhiming Li, Lugui Qiu, Mei Dong, Xiaobing Huang, Yi Luo, Xiaodong Wang, Xin Wang, Jianqiu Wu, Jingyan Xu, Pingyong Yi, Jianfeng Zhou, Hongming He,

5. High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma.  Annals of Hematology. (2015) 94:79–88. IF: 2.63  Ya-Jun Li, Zhi-Ming Li, Zhong-Jun Xia, Su Li, Yi Xia, Hui-Qiang Huang, Jia-Jia Huang, Ping-Yong Yi (Corresponding author), Wen-Qi Jiang

6. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.   Tumor Biology. (2014) 35:11809–11817. IF: 2.84 Ying-hui Song, Mei-zuo Zhong, Ping-ping Gan, Ping-Yong Yi, You-hong Tang, Yi-ping Liu, Jin-qiong Jiang, Li Li

7. Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect.   Cancer. 2005 Apr 1;103(7):1519-28. IF: 4.9  Pingyong Yi, Hai Yu, Wenxue Ma, Qingqing Wang, Boris R. Minev

8. A novel anticancer approach: SEA-anchored tumor cells expressing heat shock protein 70 onto the surface elicit strong anticancer efficacy.   Immunology letters. 2005 Oct 15;101(1):71-80. IF: 2.37  Changxin Huang, Hai Yu, Qingqing Wang, Guangen Yang, Wenxue Ma, Dajing Xia, Xiaohong Chen, Pingyong Yi, Fengping Shen, Haiya Zheng, Xeutao Cao

9. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene.  Cancer Sci. 2004 Feb;95(2):160-7. IF: 3.53  Changxin Huang, Hai Yu, Qingqing Wang, Wenxue Ma, Dajing Xia, Pingyong Yi, Lihuang Zhang and Xuetao Cao

10.BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma, Biochem. Biophys. Res. Commun. 491 (2017) 939-945.  IF: 2.559，Li Jin Qian Changgeng Zhou Qianqian Li Jiwei Li Kunlun Yi Pingyong  Biochem Biophys Res Commun ,2017,491:939-945  

11.Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study.  IF: 1.894，Li Jin Li Yajun Zhong Meizuo Liu Xianling Song Yinghui Li Jiwei Li Kunlun Yi Pingyong  Med Sci Monit, 2018,24: 2683-2692 

 12.A Multicenter Retrospective Comparison of Sequential versus Sandwich  Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. IF: 3.249，Li J. Li Y. Zhong M. Liu W. Liu X. Li J. Li K. Yi P. J Cancer, 2018,9(9): 1598-1606.

 13.Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. IF: 7.333，Shi Y. Jia B. Xu W. Li W. Liu T. Liu P. Zhao W. Zhang H. Sun X. Yang H. Zhang X. Jin J. Jin Z. Li Z. Qiu L. Dong M. Huang X. Luo Y. Wang X. Wang X. Wu J. Xu J. Yi P. Zhou J. He H. Liu L. Shen J. Tang X. Wang J. Yang J. Zeng Q. Zhang Z. Cai Z. Chen X. Ding K. Hou M. Huang H. Li X. Liang R. Liu Q. Song Y. Su H. Gao Y. Liu L. Luo J. Su L. Sun Z. Tan H. Wang H. Wang J. Wang S. Zhang H. Zhang X. Zhou D. Bai O. Wu G. Zhang L. Zhang Y. J Hematol Oncol, 2017,10(1): 69

14. 易平勇,吕慰,李春艳,吴艳琼,周佳,朱倩翎,任迪莎,雷姗姗,范培芝.吡咯替尼联合5-氟尿嘧啶抑制HER2阳性表达乳腺癌细胞的增殖及其可能的机制[J].肿瘤,2023,43(3):186-198.DOI:10.3781/j.issn.1000-7431.2023.2003-0223.

15. .易平勇, 余海, 马文学. GPI 信号肽序列与 B7-1 基因的拼接及其真核表达载体的构建和序列分析[J]. 中國腫瘤生物治療雜誌, 2002, 9(2): 152-152.

16. 易平勇, 杨光华, 谭永淑, 等. 大肠腺癌的核形态定量分析及其在临床病理上的意义[J]. 中华病理学杂志, 1994, 23(3): 141-143.

17. .黄利军, 易平勇, 刘晰宇, 等. TAC 与 AC 方案在乳腺癌新辅助化疗中的近期疗效观察[J]. 肿瘤药学, 2012, 2(2): 123-126.

18. 孙中义, 易平勇, 刘晰宇, 等. ICE 方案和 GemOX 方案治疗复发或难治性弥漫大B细胞淋巴瘤的临床观察[J]. 中国医师杂志, 2013, 15(2): 242-244.

19. 易平勇, 余海, 马文学. 自制胸水引流器持续引流,双路免疫化疗治疗恶性胸水 (附 32 例报告)[J]. 实用肿瘤杂志, 2001, 16(6): 416-417.

20. 黄利军, 易平勇, 刘晰宇, 等. 沙利度胺联合 VAD 方案治疗多发性骨髓瘤疗效观察[J]. 中国医师杂志, 2012, 14(3): 423-425.

21. 易平勇, 杨光华. 大肠腺瘤的核形态定量研究[J]. 中国肿瘤临床, 1995, 22(5): 351-353.

22. 姚远, 易平勇, 刘晰宇, 等. 自体外周血造血干细胞移植联合大剂量化疗治疗套细胞淋巴瘤的临床观察[J]. 肿瘤药学, 2014, 4(1): 54-58.

23. 易平勇, 余海, 王青青, 等. 糖基磷脂酰肌醇锚定型小鼠 B7. 1 融合蛋白的制备及抗肿瘤作用研究[J]. 中华微生物学和免疫学杂志, 2004, 24(12): 955-959.

24. 易平勇, 陈建安. 吡喃阿霉素与阿霉素治疗乳腺癌近期疗效的对比观察[J]. 用肿瘤杂志, 2000, 15(3): 206-207.

25. 易平勇, 余海, 马文学, 等. 共刺激分子 B7. 1 和葡萄球菌肠毒素 A 膜表面共修饰瘤苗抗肿瘤作用的研究[J]. 中华医学杂志, 2004, 84(18): 1567-1571.

26. 徐亚琨, 易平勇, 谢宇, 等. mB7. 1-GPI 膜表面修饰的结肠癌细胞疫苗的抗肿瘤作用研究[J]. 肿瘤药学, 2012, 2(4): 279-282.

27. 周芳, 易平勇, 刘晰宇, 等. 自体造血干细胞移植治疗多发性骨髓瘤疗效分析[J]. 中外医学研究, 2011, 9(20): 28-29.

28. 孙中义, 易平勇, 刘晰宇, 等. 自体造血干细胞移植治疗复发弥漫大 B 细胞淋巴瘤的疗效观察[J]. 肿瘤药学, 2013 (2): 111-114.

29. 贺军侨, 易平勇, 刘晰宇, 等. GemOXD 与 GDP 方案治疗复发或难治性弥漫大 B 细胞淋巴瘤的疗效对比观察[J]. 中国医师杂志, 2013, 15(7): 963-965.

30. 易平勇, 杨光华. 核形态定量在中度分化大肠腺癌异质性分析中的价值[J]. 华西医科大学学报, 1994, 25(4): 449-451.

31. 贺军侨, 易平勇, 刘晰宇, 等. R-CHOP 和 CHOP 方案治疗早期原发性胃弥漫大 B 细胞淋巴瘤的疗效和毒性比较[J]. 肿瘤药学, 2013, 3(3): 208-212.

32. 易平勇, 杨光华, 谭永淑. 核形态定量在中度分化大肠腺癌异质性分析中的价值 The Value of Nuclear Morphometry in Analysing Heterogeneity of Grade-Ⅱ Colorectal Adenocarcinomas[J]. 四川大学学报 (医学版), 1994 (04).

33. 22.黄利军, 李基炜, 李昆仑, 易平勇, 刘晰宇, 周芳, .. 姚远. (2016). 皮下脂膜炎样 T 细胞淋巴瘤 4 例并文献复习.肿瘤药学, 6(6), 466-470.、

34. 李基炜, 李昆仑, & 易平勇. (2017). 早期鼻型结外 NK/T 细胞淋巴瘤治疗进展. 中国医师杂志, (2017 年 01), 152-155.

35. 26.易嘉宁, 谢承霖, 马莹, 等. 淋巴瘤外周造血干细胞 IgH 及 TCRγ 基因重排的检测及临床意义[J]. 中国医师杂志, 2014, 16(008): 1109-1112.

36. 27.易平勇, 刘晰宇, 周芳, 等. 低剂量沙利度胺和低剂量地塞米松在多发性骨髓瘤治疗中的应用[J]. 中国医师杂志, 2013, 15(003): 385-387.

37. 28.周倩倩, 易嘉宁, 易平勇. 原发中枢神经系统淋巴瘤治疗进展[J]. 肿瘤药学, 2015, 5(3): 161-167.

38. 29.易平勇, 孙中义, 欧阳周, 等. 单倍体异基因造血干细胞移植治疗结外 NK/T 细胞淋巴瘤 1 例[J]. 中国肿瘤临床, 2014, 41(19): 1253-1253.

39. 30.周倩倩, 欧阳周, 姚远, & 易平勇. (2017). P-GEMOX 方案诱导治疗母细胞性浆细胞样树突状细胞肿瘤持续缓解一例并文献复习. 白血病. 淋巴瘤, 26(4), 235-237.

40. 31.易平勇, 孙中义, 欧阳周, 等. 非清髓性异基因造血干细胞移植治疗 T 细胞淋巴瘤的初步临床观察[J]. 中国医师杂志, 2015, 17(003): 459-462.

41. 32.16.姚远, 易平勇, 刘晰宇, 周芳, 孙中义, 欧阳周, ... & 黄利军. (2014). 自体外周血造血干细胞移植支持下大剂量化疗一线治疗外周 T 细胞淋巴瘤. 中国医师杂志, 7(2), 2.

42. 33.21.孙中义, 易平勇, 刘晰宇, 等. 大剂量化疗联合自体造血干细胞移植一线治疗弥漫大 B 细胞淋巴瘤[J]. 中国医师杂志, 2013, 15(005): 679-681.

Prestasi dan Kehormatan Akademik:

   1 Yayasan Ilmu Pengetahuan Alam Provinsi Hunan, 3 Departemen Sains dan Teknologi Provinsi Hunan, 1 Komisi Kesehatan Provinsi Hunan

Memenangkan hadiah kedua Penghargaan Teknologi Baru Rumah Sakit Kanker Provinsi Hunan pada tahun 2012

Memenangkan hadiah kedua Penghargaan Inovasi Teknologi Medis Rumah Sakit Kanker Provinsi Hunan pada tahun 2013

Penunjukan Editorial dan Akademik:

Anggota Dewan Redaksi "Farmasi Onkologi"

Direktur Eksekutif Asosiasi Anti-Kanker Hunan

Ketua Komite Profesional Tumor Hematologi Asosiasi Anti Kanker Hunan

Pemimpin Kelompok Profesional Limfoma Asosiasi Medis Provinsi Hunan

Anggota Komite Tetap Komite Profesional Limfoma Asosiasi Anti-Kanker Tiongkok

Anggota Komite Profesional Tumor Hematologi dari Asosiasi Anti-Kanker Tiongkok

Wakil Ketua Komite Profesional Limfoma dari Asosiasi Penelitian Onkologi Klinis Tiongkok Selatan

Anggota Komite Profesional Kemoterapi Tumor dari Asosiasi Medis Provinsi Hunan

Anggota Komite Profesional Hematologi Asosiasi Medis Provinsi Hunan

Anggota Cabang Dokter Hematologi dari Asosiasi Medis Hunan

Anggota Komite Pengobatan Perawatan Kritis Onkologi dari Asosiasi Anti-Kanker Hunan